These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23056237)

  • 1. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.
    Ostroff RM; Mehan MR; Stewart A; Ayers D; Brody EN; Williams SA; Levin S; Black B; Harbut M; Carbone M; Goparaju C; Pass HI
    PLoS One; 2012; 7(10):e46091. PubMed ID: 23056237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
    Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
    N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
    Tsim S; Alexander L; Kelly C; Shaw A; Hinsley S; Clark S; Evison M; Holme J; Cameron EJ; Sharma D; Wright A; Grundy S; Grieve D; Ionescu A; Breen DP; Paramasivam E; Psallidas I; Mukherjee D; Chetty M; Cox G; Hart-Thomas A; Naseer R; Edwards J; Daneshvar C; Panchal R; Munavvar M; Ostroff R; Alexander L; Hall H; Neilson M; Miller C; McCormick C; Thomson F; Chalmers AJ; Maskell NA; Blyth KG
    J Thorac Oncol; 2021 Oct; 16(10):1705-1717. PubMed ID: 34116230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
    Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
    Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation.
    Nuvoli B; Sacconi A; Bottillo G; Sciarra F; Libener R; Maconi A; Carosi M; Piperno G; Mastropasqua E; Papale M; Camera E; Galati R
    Biomed Pharmacother; 2024 Jun; 175():116662. PubMed ID: 38692064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calretinin as a blood-based biomarker for mesothelioma.
    Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
    BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.
    Sato T; Suzuki Y; Mori T; Maeda M; Abe M; Hino O; Takahashi K
    Cancer Med; 2014 Oct; 3(5):1377-84. PubMed ID: 25045139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
    Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
    Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
    Hollevoet K; Van Cleemput J; Thimpont J; De Vuyst P; Bosquée L; Nackaerts K; Germonpré P; Vansteelandt S; Kishi Y; Delanghe JR; van Meerbeeck JP
    J Thorac Oncol; 2011 May; 6(5):889-95. PubMed ID: 21358346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
    Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtiö J; Hjerpe A
    Mol Cell Proteomics; 2014 Mar; 13(3):701-15. PubMed ID: 24361865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
    Pantazopoulos I; Boura P; Xanthos T; Syrigos K
    Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J; Musk AW; Robinson BW
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
    Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
    Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
    de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
    Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
    BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.